Head and neck squamous cell carcinoma

This early-phase trial tests a new mRNA vaccine called PAN-NeoVax, designed by artificial intelligence to target multiple cancer types. The vaccine is injected directly into tumors in 9 patients with advanced solid cancers who have run out of standard options. The main goal is to…

This study tests a new vaccine called Modi-1, designed to train the immune system to attack cancer cells. It is given as a tiny shot into the skin using a special microneedle device. The trial includes 168 people with advanced triple-negative breast cancer, head and neck cancer, …

This early-stage trial tests a new treatment called VLPONC-01, which is injected directly into head and neck tumors. It delivers a substance (IL-12) that may help the immune system attack the cancer. Some participants will also receive the immunotherapy drug pembrolizumab. The ma…

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 470 adults will tak…

This early-phase trial tests the safety of CRD3874-SI, a drug that activates the STING pathway to boost the immune system against cancer. About 81 adults with advanced solid tumors (sarcoma, Merkel cell carcinoma, and others) will receive weekly IV infusions at increasing doses. …

This phase II trial is testing whether the combination of cabozantinib (a targeted therapy) and nivolumab (an immunotherapy) can shrink or stabilize advanced melanoma and head and neck cancers that have stopped responding to prior immunotherapy. Researchers are also checking if t…

This early-stage trial tests an experimental medicine called BI 3822971 in adults with advanced or metastatic solid cancers, such as lung, head and neck, breast, esophageal, bladder, vulvar, or cervical cancer, who have no standard treatment options left. The goal is to find out …

This study tests whether a combination of drugs (pembrolizumab and N-803, with or without special immune cells called PD-L1 t-haNK cells) can help shrink head and neck cancers before surgery. About 40 adults with untreated, HPV-negative head and neck cancer will receive these tre…

This trial tests an experimental drug called ASP388B, given alone or alongside standard cancer therapies, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second tests that dose in…

This study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

This trial tests whether a high-intensity interval training (HIIT) program can help head and neck cancer patients maintain or improve muscle mass after chemoradiotherapy. Researchers will use imaging and blood tests to see if changes in muscle and inflammation markers can predict…

This study tests a new drug called GI-108 in people with advanced or metastatic solid tumors, including lung, head and neck, pancreatic, and kidney cancers. The drug is designed to boost the immune system's ability to fight cancer. The trial will first find the safest dose, then …

This early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…

This study compares two radiotherapy schedules for people with head and neck cancer who begin radiation more than 6 weeks after surgery. One group gets standard treatment (5 days a week), the other gets an accelerated schedule (6 days a week). The goal is to see if the faster sch…

This phase 2 trial tests a new approach for patients with resectable head and neck squamous cell carcinoma. It combines an engineered mitochondrial vaccine (IMP3-Mito) with an immune checkpoint inhibitor (PD-1 inhibitor) given before and after surgery. The goal is to improve the …

This study tests a new treatment called iC9-CAR.CSPG4 T cells for people with head and neck cancer that has come back after standard treatments. The therapy uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The main goals are to fin…

This study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…

This study tests a vaccine made from candida (a type of yeast) to see if it can reduce the risk of head and neck cancer coming back. About 100 adults who have finished cancer treatment and are currently cancer-free will receive either the vaccine or a placebo over two years. The …

This study compares a newer, precise radiation method called stereotactic body radiotherapy (SBRT) with standard radiation therapy for people with advanced head and neck cancer who cannot have curative treatment. About 196 adults will be randomly assigned to one of the two radiat…

This early-phase study tests whether adding the experimental drug ipatasertib to standard chemotherapy and radiation is safe and effective for people with advanced head and neck cancer. Ipatasertib may help stop cancer cell growth. About 46 participants will receive the combinati…

This study is testing a new experimental drug called GI-101, given alone or with pembrolizumab or lenvatinib, in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults w…

This study compares two treatments after surgery for stage III-IVA head and neck cancer: radiation alone versus radiation plus the chemotherapy drug cisplatin. The goal is to see which approach better prevents the cancer from returning, especially in patients with certain TP53 ge…

This phase 2 trial tests a drug called becotatug vedotin, given alone or with immune-boosting drugs (penpulimab or ivonescimab), before surgery for head and neck cancer. The goal is to see if these treatments can shrink tumors or even make them disappear completely. The study inv…

This phase II trial is testing whether adding chemotherapy or chemo-immunotherapy before standard salvage surgery can improve outcomes for patients with PD-L1 positive head and neck cancer that has come back. About 180 participants will receive either carboplatin and paclitaxel, …

This phase 2 trial is testing an experimental drug called volrustomig, either alone or with chemotherapy, in people with advanced cervical, head and neck, esophageal, or mesothelioma cancers. The study aims to see if the drug can shrink tumors and how safe it is. About 257 partic…

This trial tests a new drug called TUB-030 in adults with advanced solid tumors, including head and neck, lung, and breast cancers. The goal is to find the safest and most effective dose. Participants receive the drug every three weeks and are monitored for side effects and tumor…

Researchers are testing whether giving becotatug vedotin, pucotenlimab, and cisplatin before surgery can shrink locally advanced EGFR-positive head and neck squamous cell carcinoma. The trial enrolls 40 adults with stage III or IV disease who have not yet received treatment. Part…

This early-phase study tests a new drug called EPI-326 in about 110 people with advanced lung or head & neck cancers that have specific EGFR mutations. The drug is a bispecific antibody designed to target cancer cells more precisely. The main goals are to check safety, find the r…

This phase 3 trial tests whether giving re-radiation with chemotherapy followed by the immunotherapy drug pembrolizumab can help people with recurrent head and neck cancer live longer compared to standard pembrolizumab alone or with chemotherapy. The study includes 214 adults who…

Researchers are testing two investigational radiopharmaceuticals in adults with advanced solid tumors, including colorectal, pancreatic, biliary tract, gastric, esophageal, and head and neck cancers. First, participants receive SKL35502, an imaging agent that highlights tumors ca…

This early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…

This study tests a new drug called TAK-505 in adults with advanced solid tumors that cannot be removed by surgery. The main goals are to check safety, find the best dose, and see if the drug can shrink or slow cancer growth. About 151 people with certain cancers, such as stomach,…

This phase 1 trial is testing a new drug called ADCE-T02 in people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target a protein called tissue factor found on many cancer cells. The main goals are to…

This study tests a new drug called SKB571 in 30 adults with head and neck cancer that has returned or spread and cannot be removed by surgery. The goal is to see if the drug can shrink tumors and how safe it is. Participants will receive the drug and be monitored for response and…

This study tests whether adding cetuximab to standard immunotherapy (pembrolizumab) helps people with advanced head and neck cancer that has stopped responding to platinum chemotherapy live longer. About 158 adults with cancer that has returned or spread will receive either pembr…

This phase 2 trial tests an experimental drug called ficerafusp alfa, which targets two proteins that help tumors grow, when given with the immunotherapy pembrolizumab. The study enrolls adults with recurrent or metastatic head and neck squamous cell carcinoma that has not been t…

This study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink advanced head and neck cancers more than the immunotherapy alone. About 44 people with stage III-IV head and neck cancer will receive either the comb…

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

This early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…

This early-phase study tests an experimental drug called PF-08046876 in about 310 adults with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas that have not responded to standard treatments. The drug is a type of 'antibody drug conjugate' designed to s…

This phase III trial compares an experimental drug called MRG003 with two standard treatments, cetuximab and methotrexate, in adults with recurrent or metastatic squamous cell carcinoma of the head and neck. Participants must have already tried and failed both a PD-1/PD-L1 inhibi…

This large Phase 3 trial tests whether an experimental immunotherapy drug called volrustomig can help prevent cancer from returning in people with locally advanced head and neck cancer who have finished chemoradiation. About 1,145 participants will either receive volrustomig or b…

This study tests an experimental drug called IDP-001 in people with advanced or metastatic solid tumors, including certain lung, head and neck, and other cancers. The trial has two phases: first to check safety and find the right dose, then to see if the drug can shrink tumors. A…

This early-phase trial is testing whether a drug called camonsertib, combined with a precise type of radiation, can help control head and neck cancers that have come back or cannot be removed by surgery. About 39 adults with these cancers will receive the drug along with focused …

This study tests whether extra dental care every three months for three years can prevent or reduce late side effects like dry mouth, cavities, and jaw stiffness in head and neck cancer survivors. 300 adults who completed radiation or chemoradiation will either get this extra sup…

This trial compares two treatments for advanced head and neck squamous cell carcinoma. One group receives standard chemoradiation, which combines radiation with the chemotherapy drug cisplatin. The other group receives hyperfractionated radiation, which delivers a higher total do…

This phase 2 study tests whether adding the experimental drug VS-101 to standard chemoradiotherapy helps shrink tumors in 30 adults with head and neck cancer. Participants are randomly assigned to receive VS-101 plus chemoradiation or chemoradiation alone. The main goal is to see…

This study tests a new drug called PYX-201 combined with pembrolizumab in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the combination can shrink tumors. About 220 adults with certain cancers like head an…

This early-phase trial tests whether adding mild heat therapy (thermotherapy) to standard chemoradiation is safe and tolerable for people with advanced head and neck cancer. The heat, applied once a week, aims to make the cancer more sensitive to treatment. The study includes two…

This early-phase study tests an experimental therapy called FT836, a ready-made CAR T-cell treatment, in people with advanced solid tumors like lung, colorectal, breast, ovarian, endometrial, or head and neck cancers that have not responded to prior treatments. The main goals are…

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

This phase II trial is testing whether combining low-dose radiotherapy with the immunotherapy drug Toripalimab before surgery can improve outcomes for people with advanced head and neck squamous cell carcinoma. About 22 participants will receive two cycles of the combination, the…

This early-stage trial tests a new drug called JNJ-95437446 in people with advanced solid tumors, including colorectal cancer, that have not responded to standard treatments. The study has two parts: first, finding a safe dose, and second, checking safety more closely in a larger…

This phase 3 trial tests whether injecting NBTXR3 nanoparticles into tumors before radiation therapy can improve outcomes for elderly patients with advanced head and neck cancer who cannot receive chemotherapy. About 500 participants will be randomly assigned to receive either ra…

This Phase 3 trial is testing whether adding the targeted drug amivantamab to standard immunotherapy and chemotherapy can help people with advanced head and neck cancer live longer. About 500 participants who have not had prior treatment for their recurrent or metastatic cancer w…

This early-stage study is testing whether a new drug, JNJ-90301900, is safe and works when injected directly into tumors along with standard chemotherapy and radiation. It involves 30 adults with advanced head and neck cancer. The main goal is to check for side effects and see ho…

This phase II trial tests a treatment called boron neutron capture therapy (BNCT) for people with head and neck cancers that have returned and cannot be removed with surgery. Patients receive an injection of a boron-containing compound, B10 L-BPA, which is absorbed by cancer cell…

This study tests a drug called amivantamab, either alone or combined with other cancer drugs (pembrolizumab, paclitaxel, carboplatin), in people with head and neck cancer that has spread or come back. The goal is to see if these treatments are safe and can shrink tumors. About 28…

This early-phase study tests a new drug called STRO-004 in adults with advanced solid tumors that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in more patients, and combining STRO-004 with another d…

This phase II trial tests whether a personalized, reduced-volume radiation plan can safely lower side effects after surgery for head and neck cancer. About 50 patients will receive radiation only to high-risk areas, skipping some traditionally treated zones. The goal is to see if…

This trial is testing whether an experimental DNA vaccine called VB10.16, when combined with the standard immunotherapy drug pembrolizumab, can help people with a type of head and neck cancer linked to HPV16. The study includes adults with recurrent or metastatic cancer in the or…

This early-phase trial tests a new drug called STC-15, either alone or combined with an immunotherapy drug (toripalimab), in people with advanced solid tumors or certain sarcomas. The study aims to check safety and whether the drugs shrink tumors. About 107 participants will be e…

This early-phase trial tests an investigational drug called ABBV-400 in about 300 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The study aims to see if the drug can shrink tumors and to check for side effects. Participants receive A…

This phase II trial is testing whether the immunotherapy drug pembrolizumab (Keytruda) alone can work better than the usual combination of chemotherapy and radiation after surgery for head and neck cancer that has come back or is a new primary tumor. About 188 adults aged 18-79 w…

This phase II trial is testing whether adding the immunotherapy drug sintilimab to a regimen of radiation and chemotherapy can improve outcomes for people with locally advanced head and neck squamous cell carcinoma. Participants will receive sintilimab alongside a short course of…

This Phase 1 trial tests two experimental mRNA immunotherapies, mRNA-4106 and mRNA-4200, in about 42 people with advanced solid tumors. Unlike personalized cancer vaccines made from a patient's own tumor mutations, these are off-the-shelf therapies designed to target shared antig…

This early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…

This Phase 2 trial tests whether adding fianlimab to cemiplimab works better than cemiplimab alone for people with advanced head and neck cancer that has come back or spread. About 120 participants whose tumors have a specific marker (PD-L1 positive) will receive either the drug …

This early-stage trial tests a new therapy made from cord blood immune cells that are engineered to better target and attack head and neck cancer cells. Up to 33 patients with advanced disease that has not responded to standard treatments will receive these cells along with low-d…

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…

This study tests a milder combination of chemotherapy, immunotherapy, and radiation for adults aged 65 and older with head and neck cancer who are considered frail. The goal is to see if more patients can complete the full treatment course. The regimen is tailored based on a biom…

This early-phase study tests an experimental drug called ABBV-711, alone or with another drug (budigalimab), in adults with advanced squamous tumors (like certain lung or head and neck cancers). The main goals are to check safety and see if the tumors shrink. About 220 people wil…

This study tests a new drug, AZD6750, that helps the immune system fight cancer. It is for adults with advanced solid tumors like melanoma, lung, or breast cancer that have not responded to other treatments. The goal is to find the safest dose and see if it shrinks tumors when us…

This early-phase trial tests a radioactive drug called Y-NM600 in people with metastatic cancer who are already receiving immunotherapy (anti-PD-1 or anti-PD-L1). The goal is to see if adding Y-NM600 is safe and can make the immunotherapy work better. Up to 60 participants will b…

This phase 2 trial is testing a combination of three therapies—modified immune cells (PD-L1 t-haNK), an immune-boosting protein (NAI/Anktiva), and a targeted antibody (cetuximab)—in 25 people with recurrent or metastatic head and neck cancer that has not responded to prior immuno…

This early-phase trial is testing a new drug called NRM-823, alone or with immunotherapy, in people with advanced solid tumors like lung, ovarian, or breast cancer that haven't responded to standard treatments. The study aims to see if the drug is safe and tolerable. About 150 pa…

This study compares two treatments for people with advanced head and neck cancer who cannot use the standard drug cisplatin. About 454 participants will receive either cetuximab (a targeted antibody) or a chemotherapy combo (carboplatin + paclitaxel) alongside precise radiation t…

This study tests a new drug called BMS-986340, alone or with other cancer treatments, in people with advanced solid tumors like lung, colon, or breast cancer. The goal is to find safe doses and check for side effects. About 1,100 adults with tumors that have worsened after standa…

This study tests personalized radiotherapy approaches for people with lung cancer, brain metastases, or other solid tumors. It aims to see if adapting radiation based on how a patient responds is safe and effective. About 45 adults will participate, receiving either extra radiati…

This early-stage trial tests a new drug called YL211 in 155 people with advanced solid tumors who have no standard treatment options left. The study has three parts: first, finding a safe dose; then, confirming that dose; and finally, testing how well it works. The main goals are…

This study tests a new drug called GTAEXS617 in people with advanced solid tumors (like lung, pancreatic, or ovarian cancer) that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 230 p…

This study tests an experimental drug called SMP-3124LP, which is a liposomal (fat-encapsulated) version of a cancer-fighting compound. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding the safest d…

This study tests whether giving lower doses of radiation to certain head and neck cancer patients can still effectively treat the cancer while causing fewer side effects. Participants receive chemotherapy and radiation, and doctors use a special PET scan to decide who can get the…

This early-phase study tests a new treatment called MQ710, a modified virus injected directly into tumors, alone or with the immunotherapy drug pembrolizumab. It is for people with advanced solid tumors (like skin cancer or head and neck cancer) that have not responded to standar…

This early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…

This early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…

This early-phase trial is testing a new drug called BMS-986517 in about 315 adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that the drug …

This trial is testing whether it is safe to skip radiation to certain low-risk areas of the neck after surgery for head and neck cancer. The goal is to see if this approach can reduce side effects and preserve quality of life while still keeping the cancer from coming back. Parti…

This early-stage trial is testing an experimental drug called DM005 in 136 people with advanced solid tumors, including lung, head and neck, and other cancers that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and se…

This study looks at whether people with advanced head and neck cancer who had a good response to chemo-immunotherapy before surgery can safely avoid low-dose radiation to the neck afterward. The goal is to maintain cancer control while reducing side effects and improving quality …

This study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…

This trial tests whether a smartphone app can help patients with head and neck cancer maintain their nutritional status during and after radiation therapy. Participants will use the app to regularly report their diet and well-being, with the goal of reducing weight loss and malnu…

This trial tests whether adding radiotherapy to the immunotherapy drug pembrolizumab (with or without chemotherapy) helps people with newly diagnosed head and neck cancer that has spread to other parts of the body. Participants receive either standard systemic treatment alone or …

This phase 2 pilot study is testing a new drug called CUE-101, alone or combined with pembrolizumab, in 30 people with newly diagnosed, locally advanced HPV-16 head and neck cancer. The goal is to see if the combination boosts the immune system's ability to fight the cancer befor…

This early-phase trial is testing an experimental drug called INBRX-106, alone or combined with the immunotherapy Keytruda, in people with advanced solid tumors (including lung, head and neck, melanoma, and others) that have stopped responding to standard treatments. The main goa…

This trial is testing an experimental drug called petosemtamab (MCLA-158) in people with advanced solid tumors, including colorectal, head and neck, and lung cancers. The drug is a bispecific antibody designed to block two cancer-related proteins, EGFR and LGR5. Researchers want …

This early-stage study is testing an experimental drug called CTX-8371 in people with advanced lung, breast, lymphoma, head and neck, or skin cancers that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 85 parti…

This early-phase study tests a new drug called SLV-154 in about 70 people with advanced solid tumors (like head and neck, lung, breast, or ovarian cancer) that have spread. The main goal is to find a safe dose and check for side effects. Researchers will also watch for any signs …

This early-phase trial is testing whether adding the immunotherapy drug pembrolizumab (Keytruda) to radiation therapy before and during surgery can help treat head and neck cancers that have persisted or come back. About 45 adults with resectable tumors will receive the combinati…

This early-stage trial is testing a new drug called IBI3028 in people with advanced solid tumors that cannot be removed by surgery or have spread. The drug works by attaching to two proteins (EGFR and c-Met) found on some cancer cells and delivering two anti-cancer agents directl…

This phase II trial is testing whether a combination of an experimental drug (BL-B01D1) and a PD-1 monoclonal antibody can shrink tumors in people with recurrent or metastatic head and neck squamous cell carcinoma (non-nasopharyngeal type) and other solid tumors. The study enroll…

This trial is investigating whether giving tislelizumab (an immunotherapy drug) combined with chemotherapy for 2 cycles before surgery works as well as 4 cycles in people with locally advanced head and neck squamous cell carcinoma. The study aims to find the best balance between …

This early-stage study tests a new drug called DAY301 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a powerful toxin directly to cancer cells while sparing healthy ones. The study aims to find the safest dose …

This early-stage study tests a new drug called PF-08046054/SGN-PDL1V, alone or with another drug (pembrolizumab), in people with advanced solid tumors like lung, head and neck, esophageal, breast, stomach, endometrial, pancreatic, or liver cancer. The main goals are to find safe …

This early-stage study is testing whether adding the immunotherapy drug cemiplimab to standard chemotherapy and cetuximab before surgery is safe for people with advanced head and neck cancer. The goal is to see if this combination can control the cancer well enough that patients …

This study tests a combination of two investigational drugs, SHR-A2102 and adebrelimab, with or without other anti-cancer therapies, in people whose head and neck squamous cell carcinoma has returned or spread. The goal is to find safe and effective doses and see if the combinati…

This phase 2 trial is testing the drug cetuximab by itself in people with head and neck cancer that has come back or spread. Participants have already tried immunotherapy (PD-1 inhibitors) and it stopped working or caused side effects. The study will measure how many patients see…

This study tests whether adding an experimental drug called ficerafusp alfa to the immunotherapy pembrolizumab (Keytruda) works better than pembrolizumab alone for people with PD-L1-positive head and neck cancer that has spread or returned. About 650 adults will be randomly assig…

This study tests a combination of a modified virus (H101) and a targeted chemotherapy procedure (TACE) in 20 adults with head and neck cancer that has returned or spread after at least two standard treatments. The goal is to shrink tumors and boost the immune system while limitin…

This early-stage trial is testing the safety and best dose of the drug decitabine when added to standard surgery, radiation, and chemotherapy for people with HPV-negative head and neck cancer that can be surgically removed. Decitabine may help make cancer cells more sensitive to …

This study tests an experimental mRNA therapy called mRNA-4359, given alone or with standard immunotherapy drugs, in people with advanced solid tumors (like melanoma, lung cancer, or colorectal cancer). The main goals are to find a safe dose and see if the treatment can shrink tu…

This phase 2 trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy (cisplatin and docetaxel) is safe and tolerable as an initial treatment for people with advanced head and neck cancer. The study enrolls 26 adults whose tumors have a certain prote…

This phase II trial tests whether adding the targeted drug nimotuzumab to immunotherapy and chemotherapy before surgery can improve outcomes for people with locally advanced head and neck cancer. About 182 participants will receive the combination or standard treatment. The main …

This early-stage trial tests a new drug called BHV-1530 in about 95 adults whose solid tumors have spread or cannot be removed. The main goals are to find a safe dose and check for side effects. Researchers will also watch for signs that the drug shrinks tumors or slows the disea…

This phase II trial tests whether combining two drugs—pucotenlimab (an immunotherapy) and becotatug vedotin (a targeted chemotherapy)—given before and after surgery can improve outcomes for people with locally advanced head and neck cancer. About 80 participants will receive eith…

This trial tests a vaccine called BVAC-E6E7 in people with head and neck cancer linked to HPV types 16 or 18 that cannot be removed by surgery or has spread. The vaccine is designed to teach the immune system to attack cancer cells. The study first checks safety and the best dose…

This trial investigates whether adding ivonescimab—a drug that targets both PD-1 and VEGF—to standard chemotherapy can shrink locally advanced oral or oropharyngeal cancers before surgery. About 20 adults with resectable stage II–IVA disease will receive two cycles of the combina…

This study tests a new experimental drug called HCB101 combined with the immunotherapy pembrolizumab in 50 adults with head and neck cancer that has stopped responding to platinum chemotherapy. The goal is to see if the combination is safe and can shrink tumors. Participants rece…

This early-stage trial is testing a new drug called sigvotatug vedotin, alone or with other cancer medicines, in people with advanced solid tumors like lung, head and neck, and breast cancers. The study aims to find a safe dose and check for side effects. About 1,000 participants…

This study is testing whether combining radiation therapy (proton or X-ray) with the immunotherapy drug pembrolizumab before surgery is safe and effective for people with recurrent head and neck cancer. The trial has two phases: the first checks safety and the right dose, and the…

This early-phase study tests a new drug called PYX-201 in people with advanced solid tumors that have come back or spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 330 adults with certain breast, head and neck, or other cancers are being…

This study tests a new drug called ALE.P02 in people with advanced squamous cell cancers of the lung, head and neck, cervix, or esophagus that have spread or cannot be removed. The goal is to find the safest and most effective dose and see if it can shrink tumors. About 170 adult…

This phase II trial is testing whether the drug ivonescimab, given before surgery, can shrink tumors in people with stage II-IV head and neck cancer that can be removed. Ivonescimab is a type of antibody that helps the immune system fight cancer. The study will enroll 28 adults w…

This study tests a new drug called XTX301 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in specific cancer types. Researchers will monitor side effects and wheth…

This phase 2 trial is testing whether adding common diabetes drugs (metformin or rosiglitazone) to standard immunotherapy (nivolumab or pembrolizumab) can improve treatment for several advanced solid tumors, including melanoma, lung cancer, and liver cancer. About 72 participants…

This phase 2 trial is testing a special form of the chemotherapy drug paclitaxel, called polymeric micelles, combined with carboplatin in 29 people with recurrent or metastatic head and neck squamous cell carcinoma. The goal is to see how well the treatment shrinks tumors and to …

This early-stage study tests a new drug called azirkitug, alone or with other cancer medicines, in people with advanced solid tumors like lung, head/neck, and pancreatic cancers. The goal is to find safe doses and check side effects. About 694 adults will take part worldwide, rec…

This phase 2 trial tests whether giving the immunotherapy drug pembrolizumab along with chemotherapy before surgery, followed by pembrolizumab alone for about a year after surgery, can improve outcomes for people with recurrent head and neck cancer. The study aims to see if this …

This early study tests an experimental drug called XB010, alone or combined with the immunotherapy pembrolizumab, in people with advanced solid tumors (like lung, breast, or head and neck cancers) that have stopped responding to other treatments. The main goals are to find a safe…

This phase II trial tests a combination of two drugs, sacituzumab tirumotecan and toripalimab, as a first treatment for recurrent or metastatic head and neck squamous cell carcinoma. The study enrolls 39 adults whose tumors have specific markers (Trop2 and CPS). The goal is to se…

This phase 2 trial tests two drugs, Iparomlimab and Tuvonralimab, in 30 adults with recurrent or metastatic head and neck cancer that has not responded to at least two prior treatments. Participants receive the drugs by IV every 21 days. The main goal is to see if the combination…

This early-phase study is testing an experimental drug called IDE034 in 150 adults with advanced solid tumors (such as lung, ovarian, or colorectal cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see …

This early-stage trial is testing a new drug called AB821 in 50 adults with advanced melanoma or other solid tumors that respond to immune therapies. The main goal is to check safety and find the right dose. Participants receive AB821 by IV every 2 or 3 weeks for up to two years.

This study tests an experimental drug called YH32364 in adults with advanced solid tumors that have high levels of EGFR and have not responded to previous treatments. The trial has two parts: first, finding a safe dose in about 30 people, then testing that dose in 50 people with …

This early-phase study tests an experimental drug called OKN4395, taken as a pill, alone or together with the immunotherapy pembrolizumab. The goal is to find a safe dose and see if the combination can shrink tumors in people with advanced solid cancers like lung, colorectal, sto…

This phase 2 trial tests whether combining the chemotherapy 5-azacytidine with the immunotherapy nivolumab can make HPV-related head and neck cancer more responsive to treatment. About 50 people with resectable tumors will receive one or both drugs before surgery. The goal is to …

This study looks at whether getting standard immunotherapy in the morning (before 11 am) or afternoon (after 12 pm) changes how well it fights advanced or metastatic solid tumors. Researchers think the body's internal clock (circadian rhythm) might affect immune activity. About 1…

This early-stage trial is testing an experimental oral drug called EXS74539 (REC-4539) in about 40 people with various solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to check the drug's safety, find the right dose, and see how the body proce…

This Phase II trial tests whether giving a combination of two drugs—Becotatug Vedotin (a targeted chemotherapy) and Pucotenlimab (an immunotherapy)—before and after surgery can improve outcomes for people with recurrent head and neck cancer that can still be removed. About 102 pa…

This early-stage study tests a new type of cancer vaccine made from irradiated tumor and nearby cells. It aims to see if the vaccine is safe and can help the immune system fight advanced solid tumors like osteosarcoma, pancreatic cancer, and others. About 54 people will take part…

This study tests whether adding a chemotherapy drug (paclitaxel) to a targeted therapy (cetuximab) works better than cetuximab alone for people with advanced head and neck cancer that has worsened after initial treatment. About 65 adults with recurrent or metastatic squamous cell…

This early-phase trial is testing an experimental oral drug called ABBV-CLS-484, either alone or combined with other cancer treatments, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study aims to find safe and tolerable doses and to se…

This study tests a new treatment for adults with advanced head and neck cancer that has spread or come back. The treatment uses donor immune cells that are engineered to target two cancer markers, EGFR and HER2. Participants first receive chemotherapy to prepare their body, then …

This early-phase trial is testing a new drug called IACS-6274, either alone or combined with other cancer drugs, in 54 adults with advanced solid tumors (such as melanoma, ovarian, or head and neck cancers). The main goal is to find the safest dose and understand side effects. Th…

This study tests whether adding petosemtamab to the standard immunotherapy pembrolizumab helps people with advanced head and neck cancer live longer. About 700 adults with PD-L1 positive cancer that has spread or come back will receive either the combination or pembrolizumab alon…

This study tests a new drug called ifinatamab deruxtecan in people with advanced solid tumors that have not been cured by other treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 250 participants will take part, and those who benefit may …

This study tests whether adding precise, high-dose radiation (SABR) to the standard immunotherapy drug pembrolizumab can help people with head and neck cancer that has spread to 1-5 spots in the body. About 200 adults with a specific type of head and neck cancer will be randomly …

This study tests a new drug called BC3195 combined with pembrolizumab (an immunotherapy) in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if the combination can shrink tumors. About 111 adults with certain cancers will take part.

This study tests whether the drug dostarlimab, given after standard chemoradiation, can help prevent head and neck cancer from coming back or spreading. About 864 adults with advanced but not surgically removable head and neck cancer will receive either dostarlimab or a placebo. …

This early-phase trial is testing a new drug called KK2260 in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test different dosing schedules in patients with esophageal or head and neck cancers. Ab…

This study tests a drug called afatinib in 25 adults with Fanconi anemia who have advanced head and neck cancer that cannot be removed by surgery. Afatinib is a pill that blocks a protein helping cancer grow. The goal is to see if it can shrink tumors and control the disease. Res…

This study tests a new antibody called HMBD-001 combined with two existing cancer drugs (cetuximab and docetaxel) in people with advanced squamous cell cancers of the lung, head and neck, esophagus, cervix, or skin. The goal is to see if the combination is safe and can shrink tum…

This study tests two new drug combinations (DB-1311 with BNT327 or DB-1305) in 450 adults with advanced or metastatic solid tumors that have not responded to other treatments. The main goals are to check safety and see if tumors shrink. Participants must be in fairly good health …

This study tests whether adding palbociclib to cetuximab helps people with a certain genetic type of head and neck cancer live longer than cetuximab alone. Participants must have HPV-unrelated cancer with a CDKN2A gene change that has worsened after prior immunotherapy. About 81 …

This study tests a new treatment called KSQ-004EX for people with advanced solid tumors that have not responded to standard therapies. The treatment uses a patient's own immune cells (tumor infiltrating lymphocytes) that are genetically modified to be more powerful against cancer…

This Phase 3 trial is testing two new drug combinations—ivonescimab alone or with ligufalimab—against the standard treatment pembrolizumab (Keytruda) for people with advanced head and neck cancer that has come back or spread. The study will enroll about 780 participants to see if…

This study tests whether giving two drugs (lucanoximab and tagolimab) before surgery can shrink tumors in people with head and neck cancer. Thirty adults with resectable cancer will receive the drugs intravenously every two weeks for two cycles, then undergo surgery. Researchers …

This study tests a new drug called Becotatug Vedotin in children aged 2 to 18 with certain solid tumors that have come back or spread. The drug targets a protein called EGFR found on many cancer cells. The main goal is to see if the drug is safe and to find the best dose, while a…

This early-stage study is testing a new drug called ALX2004 in people with advanced lung, head and neck, esophageal, or colorectal cancers that have not responded to standard treatments. ALX2004 is an antibody-drug conjugate designed to deliver a cancer-killing payload directly t…

This phase 2 study tests whether adding occasional chemotherapy to the immunotherapy drug pembrolizumab (Keytruda) can improve outcomes for people with recurrent or metastatic head and neck cancer. A blood test that measures tumor DNA helps doctors decide when to give the chemo. …

This early-phase trial tests a new drug, UCB4594, in people with advanced solid tumors that haven't responded to standard treatments. The drug is a monoclonal antibody that targets a protein called HLA-G on cancer cells, potentially helping the immune system attack them. The stud…

This study tests a new drug, ODM-212, in about 315 adults with advanced solid tumours that cannot be cured with current treatments. The trial has two parts: first finding a safe dose, then testing that dose in more people. The main goal is to check for side effects and see how th…

This study compares a standard 6-week radiation course after surgery to a shorter 3-week course for people with head and neck cancer. The goal is to see if the shorter schedule works just as well at preventing cancer from coming back. About 369 participants will be randomly assig…

This early-stage study is testing an experimental drug called MK-6204 in about 90 adults with advanced solid tumors (such as colorectal, lung, or stomach cancer) that have not responded to standard therapies. The main goals are to check the drug's safety and find the right dose. …

This early-phase study tests a new drug called VVD-130037 in people with advanced solid tumors that have stopped responding to standard treatments. The drug aims to activate a protein (KEAP1) to fight cancer. Researchers will check safety, side effects, and whether the drug works…

This early-stage study tests two drugs (finotonlimab and stapokibart) together in 10 adults with head and neck cancer that has come back or spread. All participants have already tried standard treatments. The main goals are to see if the combination is safe and whether it shrinks…

This study compares two ways of giving the chemotherapy drug 5-FU to people with head and neck cancer that has spread or come back after prior treatments. One group gets the drug over two days every two weeks, the other over four days every three weeks. The goal is to see which s…

This phase 2 trial tests a new drug, GSK5764227, that delivers chemotherapy directly to cancer cells, either alone or with an immunotherapy called dostarlimab. The study enrolls 30 people with recurrent or metastatic head and neck cancer. Researchers will analyze tumor samples an…

This early-stage trial is testing whether giving a drug called chidamide along with a second round of radiation is safe for people whose head and neck cancer has returned after previous radiation. Only 6 participants will be enrolled to find the best dose and check for side effec…

This early study tests a new treatment called GT201, made from a patient's own tumor-fighting immune cells (TILs), combined with a PD-1 inhibitor drug. The goal is to see if this combination is safe and tolerable for 32 adults with advanced head and neck cancer that has returned …

This study tests two antibodies (iparomlimab and tuvonralimab) given together, with or without chemotherapy, for people with advanced head and neck cancer that has come back or spread after at least one prior treatment. The goal is to see if the combination can shrink tumors and …

This early-phase trial tests an experimental drug called GTB-5550 in adults with advanced solid tumors that have stopped responding to standard treatments. The drug is a nanobody designed to bridge natural killer cells to cancer cells, helping the immune system attack the tumor. …

This study tests giving chemotherapy and immunotherapy before standard surgery for head and neck cancer. The goal is to shrink tumors enough so that surgeons can perform less extensive, function-preserving operations, reducing damage to swallowing, speech, and vision. The trial e…

This phase 3 trial tests a new treatment for people with high-risk head and neck cancer who cannot receive the standard chemotherapy drug cisplatin. Participants receive radiation therapy combined with two drugs (nimotuzumab and benmelstobart) to see if this approach improves dis…

This early-phase study tests whether adding an experimental drug (CADI-05) to standard immunotherapy (pembrolizumab) can help the immune system better fight advanced head and neck cancer before surgery. About 22 adults with resectable, locally advanced disease will receive both t…

This study tests which chemotherapy combination works better when given with radiation for advanced head and neck cancer. About 120 adults with stage III or IV disease will receive either cisplatin or a mix of docetaxel and cetuximab. Researchers will also check if a tumor marker…

This early-stage trial is testing a new drug called TGW101 in people with advanced solid tumors that have not responded to other treatments. TGW101 is given in two parts: an antibody-drug conjugate and a chemical trigger that activates it. The main goal is to check safety and fin…

This early-stage trial tests a new drug called KIVU-107 in 76 adults with advanced solid tumors that have not responded to standard treatments. KIVU-107 is an antibody-drug conjugate designed to target and kill cancer cells. The main goal is to find a safe dose and check for side…

This early-stage study tests a new drug called VIR-5525, alone or with another cancer drug (pembrolizumab), in people with advanced solid tumors that have a protein called EGFR. The main goals are to check safety and find the right dose. About 450 adults with tumors that cannot b…

This phase 3 trial is testing whether adding a targeted drug (becotatug vedotin) to standard immunotherapy (a PD-1 inhibitor) before and after surgery can help people with a certain type of head and neck cancer live longer without the cancer coming back. About 430 adults with EGF…

This phase 2 trial is testing whether adding the immunotherapy drug toripalimab to standard chemotherapy can help people with advanced laryngeal or hypopharyngeal cancer avoid having their voice box removed. The study will enroll 87 adults whose cancer has not been treated before…

This Phase 3 trial is testing whether adding ficlatuzumab to the standard drug cetuximab helps people with recurrent or metastatic HPV-negative head and neck cancer live longer. About 410 adults will be randomly assigned to receive either the combination or a placebo plus cetuxim…

This trial is testing a new approach for people with head and neck cancer that has come back or spread and cannot be removed. It combines a device called DaRT, which is a tiny radioactive seed placed directly into the tumor, with the immunotherapy drug pembrolizumab (Keytruda). T…

This study tests whether adding an immunotherapy drug (pucotenlimab) to a targeted therapy (MRG003) before standard chemoradiation can shrink tumors more effectively in people with advanced head and neck cancer. About 106 adults aged 18-75 with locally advanced squamous cell carc…

This early-stage trial is testing a new treatment called VET3-TGI, a virus designed to infect and destroy cancer cells. It is being given alone or with the immunotherapy drug atezolizumab to 60 people with advanced solid tumors that have not responded to standard treatments. The …

This early-phase trial is testing a new antibody drug called ZM008, first by itself and then together with another drug (toripalimab), in people with advanced solid tumors like lung, head and neck, and pancreatic cancers. The study aims to find a safe dose and see if the combinat…

This phase 2 trial is testing whether using MRI scans to adjust radiation therapy can better protect healthy organs in people with head and neck cancer. The study will enroll 35 patients who will receive standard intensity-modulated radiotherapy, but with a personalized boost gui…

This early study tests whether using ultrasound and microbubbles can help the immunotherapy drug pembrolizumab (Keytruda) work better in people with head and neck cancer that has come back or spread. Only 6 participants will receive three rounds of treatment. The main goal is to …

This early-phase study tests a new drug called 177LuBetaBart in people with advanced solid tumors that have stopped responding to standard treatments. The drug is a radioactive antibody designed to seek out and destroy cancer cells. The study will enroll about 61 participants and…

This phase 2 trial tests whether giving two drugs—ficerafusp alfa and pembrolizumab (Keytruda)—before surgery can shrink tumors in people with advanced head and neck cancer. About 32 participants with resectable, PD-L1-positive squamous cell carcinoma will receive the combination…

This early-phase trial is testing whether a new drug called GV20-0251, combined with the immunotherapy sintilimab, is safe and can shrink tumors before surgery in people with head and neck cancer. Nine adults with advanced but removable tumors will receive two cycles of the drug …

This phase 3 trial aims to see if adding chemotherapy (cisplatin) to standard radiation therapy after surgery helps people with intermediate-risk head and neck squamous cell carcinoma live longer without the cancer returning. About 386 participants who have had surgery and show c…

This study tests whether a postbiotic supplement (Postbiotix-HLA™) can reduce immune-related side effects in 45 people with recurrent or metastatic head and neck cancer who are receiving the immunotherapy drug pembrolizumab. Participants will take either the supplement or a place…

This early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack cancer, and give them back after a short course of chemotherapy. T…

This early-phase trial is testing a new drug called DCSZ11 alongside standard chemotherapy or immunotherapy in 9 people with advanced or metastatic solid tumors, including head and neck cancer. The main goal is to see if the combination is safe and whether it can shrink tumors. B…

This early-phase trial tests whether adding a common blood pressure medication (losartan) to immunotherapy (pembrolizumab) and precise radiation (SBRT) is safe and effective for people with head and neck cancer that has returned, not responded to treatment, or spread to a few oth…

This phase 2 trial tests a new combination of drugs—imaxitinib, chemotherapy, and immunotherapy—given before surgery for advanced head and neck cancer. The goal is to see if this approach can shrink tumors more effectively, making surgery easier or possible for patients whose can…

This early-phase trial tests a combination of two newer drugs (tislelizumab and pamiparib) plus standard chemotherapy and re-radiation in 30 people whose head and neck cancer has come back. The main goal is to find a safe dose and check for side effects. Participants will be foll…

This early-phase trial tests a personalized vaccine made from a patient's own tumor cells, given alone or with the immunotherapy drug pembrolizumab, for people with head and neck cancer that has returned or spread. The main goals are to check safety, find the best dose, and see i…

This study tests a new drug called volrustomig combined with standard chemotherapy (paclitaxel and carboplatin) in people with advanced head and neck cancer that is not caused by HPV. The goal is to see if this combination shrinks tumors before further treatment is tailored based…

This study tests whether a single, extremely high dose of radiation, guided by advanced MRI technology, can control liver tumors that have spread from other cancers better than the usual high dose. About 114 adults with up to 3 liver metastases will be randomly assigned to receiv…

This study tests a combination of two drugs, MCLA-129 and ensartinib, in people with advanced solid tumors that cannot be cured. The drugs work by blocking certain proteins that help cancer grow. The trial has two phases: first to find the safest dose, then to see if the combo sh…

This study tests a new drug called HLX43 in people whose head and neck cancer has returned or spread to other parts of the body. The drug works by targeting a protein (PD-L1) on cancer cells to help the immune system attack them. About 167 adults aged 18 to 75 will take part to s…

This study tests whether giving additional immune therapy after surgery can help prevent head and neck cancer from coming back. It includes 268 adults who already had a good response to initial treatment. The goal is to see if this approach improves survival and is safe.

This phase 2 trial is testing whether giving two drugs—pembrolizumab (Keytruda) and IO102-103—before surgery is safe and effective for people with head and neck cancer. The study will enroll 30 adults whose cancer can be surgically removed. Researchers will watch for side effects…

This phase 2 trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemoradiotherapy can improve outcomes for people with locally advanced head and neck cancer. The study will enroll 27 participants and track how many remain cancer-free aft…

This phase 2 study tests a drug called AZD2936 in people with high-risk head and neck cancer who still have traces of cancer DNA in their blood after completing standard treatment. The drug is designed to boost the immune system to find and destroy these remaining cancer cells. A…

This study tests whether combining two drugs, sacituzumab govitecan and cetuximab, can shrink or control advanced head and neck cancer that has grown after initial therapy. About 40 adults whose cancer has spread or returned will receive the combination. The goal is to see how ma…

This early-phase trial is testing a new drug called 177Lu-RAD204, which is a radioactive antibody designed to seek out and destroy cancer cells that have a protein called PD-L1 on their surface. The study will involve 30 adults with advanced solid tumors (like lung, breast, or sk…

This trial tests an experimental drug called CP-383 in people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard treatments. The drug is taken daily by mouth and works by blocking a process cancer cells need to grow. The study …

This phase II trial tests whether adding lovastatin, a common cholesterol-lowering drug, to the immunotherapy pembrolizumab can help shrink tumors in people with head and neck cancer that has returned or spread. The study will enroll 28 adults whose tumors express PD-L1. Research…

This early-phase trial is testing a new drug called CLSP-1025 in about 90 adults with advanced solid tumors (like lung, colon, or breast cancer) that have a specific p53 mutation (R175H). The drug works by directing the body's immune cells to attack cancer cells carrying this mut…

This phase 2 trial is testing a new way of giving chemotherapy along with the immunotherapy drug pembrolizumab (Keytruda) for people with advanced head and neck cancer that has come back or spread. The idea is that giving chemo in short, spaced-out pulses after immunotherapy migh…

This study is testing an experimental drug called MCLA-129 in people with advanced solid tumors, including non-small cell lung cancer, head and neck cancer, and colorectal cancer. The drug is a bispecific antibody designed to attach to two cancer-related proteins (EGFR and c-Met)…

This early-stage trial tests a new combination treatment for people with advanced HER2-positive solid tumors (like breast, lung, or stomach cancer). Participants receive an injection of a special virus directly into one tumor to help the immune system attack cancer, followed by a…

This early-phase study tests a new drug called SH009 in people with advanced solid tumors (like liver, lung, breast, or stomach cancer) that have not responded to standard treatments. The main goals are to see if the drug shrinks tumors and to check its safety. About 150 adults w…

This early-phase study tests a new radioactive drug, [177Lu]Lu-AKIR001, in 15 adults with advanced solid tumors (like thyroid, head and neck, cervical, vulvar, or lung cancer) that have stopped responding to standard treatments. The main goal is to check the drug's safety and sid…

This study is testing whether people with advanced head and neck cancer who respond well to immunotherapy can have a smaller, less invasive surgery instead of the standard extensive surgery. The goal is to see if the smaller surgery works just as well at controlling the cancer wh…

This early-phase trial is testing an experimental drug called TH9619 in about 43 adults with advanced solid tumors, including colorectal, head and neck, lung, and gastric cancers. The main goal is to check the drug's safety and find the right dose. Participants must have already …

This Phase 2 trial is testing whether a combination of two drugs, SYS6010 and Enlonstobart, can shrink tumors or slow the growth of head and neck cancer that has come back or spread. About 70 adults aged 18-75 who have not had prior systemic treatment for their advanced cancer wi…

This early-phase trial is testing an experimental drug called SIM0610 in 260 adults with advanced solid tumors, including lung, colorectal, head and neck, and liver cancers. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Particip…

This phase 2 trial is testing an oral drug called NRC-2694-A combined with the chemotherapy paclitaxel in people with recurrent or metastatic head and neck squamous cell carcinoma that has worsened after immunotherapy. About 21 adults will receive the combination to see if it shr…

This study tests a new drug called OM-RCA-01, an antibody that blocks a protein called FGFR1 found on some cancer cells. About 58 adults with metastatic kidney, lung, prostate, breast, or head and neck cancers that express FGFR1 will receive the drug by IV every two weeks. The go…

This phase II trial tests a new drug called SIBP-03, given together with cetuximab, for people with advanced head and neck cancer that has returned or spread. The study will enroll 81 adults who have already tried immunotherapy and platinum chemotherapy. The goal is to see if the…

This study tests a navigation system that helps surgeons remove head and neck tumors more precisely. During surgery, the system creates a 3D map of the tumor and its edges, which is then used to plan follow-up radiation therapy. The goal is to reduce the chance of leftover cancer…

This study tests whether a shorter, more intense type of radiation (stereotactic radiotherapy given in 5 sessions) works as well as the standard longer course (20-30 sessions) for treating skin cancer that has spread to the parotid gland in the head and neck. About 90 adults who …

This study tests whether adding the targeted drug nimotuzumab to standard radiation therapy helps control advanced head and neck cancer better than radiation alone. It is for 335 adults whose cancer has spread locally but who cannot take platinum-based chemotherapy. The main goal…

This early-phase study tests a new drug called SIBP-A13 in 144 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or slow their growth. Participants will re…

This early-phase study tests a radioactive drug called lutetium BL-ARC001 in 22 people with advanced lung, breast, head and neck, or other solid tumors that have stopped responding to standard therapies. The drug is given by IV infusion over a 6-week cycle. The main goals are to …

This early-stage trial is testing a new drug called DR-0202, a bispecific antibody, in people with advanced solid tumors (such as breast, lung, and pancreatic cancers) that have not responded to at least two prior treatments. The study aims to find a safe dose and see if the drug…

This study tests whether early nutritional and medical support helps people with head and neck cancer complete their full course of radiation and chemotherapy. Many patients struggle to finish treatment due to weight loss and side effects. The study will enroll 138 adults and mea…

This early-phase study tests a new drug called BL-M24D1 in people with advanced head and neck cancer or other solid tumors that have spread. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 16 adults aged 18 to 75 will ta…

This early study tests a new mRNA vaccine (IL-22BP) for people with advanced solid tumors like sarcoma, head and neck cancer, or melanoma that have not responded to standard treatments. The vaccine is injected directly into tumors. Only 6 participants are enrolled to check safety…

This early-stage trial tests a new drug called ONM-501, which is injected directly into tumors, either alone or with the immunotherapy cemiplimab (Libtayo). The study includes 168 adults with advanced solid tumors or lymphomas that have not responded to standard treatments. The m…

This study tests a combination of three drugs (carboplatin, paclitaxel, and cetuximab) in people with advanced head and neck cancer that has returned or spread. Participants must have already tried the immunotherapy drug pembrolizumab (with or without chemotherapy) and it stopped…

This trial tests a program called ENDURE that helps head and neck cancer patients start radiation therapy within 6 weeks after surgery. The program provides education, social support, and better coordination among doctors. Researchers will compare it to usual care in 532 adults w…

This study tests an experimental drug called VMD-928, taken as a pill, either alone or with another cancer drug (pembrolizumab). It is for adults with advanced solid tumors or lymphoma that have not responded to or are no longer controlled by available treatments. The goal is to …

This early-phase trial tests a new drug called MT-4561 in about 27 people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have no standard options left. The main goals are to find a safe dose and see if the drug can shrink tumors. It is a first-in-human s…

This study tests an experimental drug called GV20-0251 in adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink tumors or slow their growth. About 350 participants with various cancers, including lung, mel…

This early-stage trial is testing a new three-drug combination for people with head and neck cancer that has come back or spread. The drugs include a targeted therapy (zanzalintinib), an immunotherapy (pembrolizumab), and another targeted antibody (cetuximab). The main goal is to…

This study tests a new drug called YL202 in people with advanced solid tumors, including lung, breast, and head/neck cancers. The goal is to see if the drug can shrink tumors and control the disease. About 200 participants will receive the drug, and researchers will monitor safet…

This early-phase study tests a new drug called LB-LR1109 in people with advanced solid tumors like lung, kidney, head and neck, bladder, or skin cancer that has not responded to standard treatments. The study first gives the drug alone, then in combination with another cancer dru…

This early-phase study tests a new drug called GV20-0251 in people with advanced solid tumors (like liver, lung, or skin cancer) that have stopped responding to standard therapies. The main goal is to check the drug's safety in a small group of 10 patients. It is not a cure, but …

This early-stage study is testing a new therapeutic vaccine called TI-0093 in 12 adults with HPV-16 positive cancers that have returned or spread. The vaccine is given as a series of five shots over about a month. The main goals are to check safety, find the best dose, and see if…

This study tests a new daily pill, VLS-1488, for people with advanced solid tumors that have not responded to other treatments. About 200 participants with specific cancers like ovarian, lung, or breast cancer will receive the drug to see if it is safe and shrinks tumors. The goa…

This study tests whether a combination of two drugs, ACR-368 and low-dose gemcitabine, can shrink tumors or slow cancer growth in people with head and neck cancer that has come back or spread. About 43 adults will receive the drugs every two weeks. The goal is to see if the treat…

This phase 3 trial tests whether a new treatment called ASP-1929 photoimmunotherapy (a light-activated drug) combined with the immunotherapy pembrolizumab works better than standard care for people with recurrent head and neck cancer that hasn't spread to other parts of the body.…

This early-stage trial tests a new treatment called T3011, a modified virus injected directly into tumors, for people with advanced solid cancers like melanoma, lung cancer, or sarcoma. The study will also test T3011 combined with the immunotherapy drug pembrolizumab (Keytruda). …

This early-stage trial is testing whether a combination of two imaging agents can help surgeons better detect and remove head and neck cancer. One agent uses a radioactive label for pre-surgery scans, and the other uses a fluorescent dye that makes cancer cells glow during surger…

This study tests two experimental drugs, BL-B01D1 and SI-B003, given alone or together, in people with head and neck cancer that has come back or spread. The goal is to see if these treatments can shrink tumors or slow the disease. About 186 adults aged 18 to 75 who have tried at…

This study is testing whether a lower dose of radiation after surgery can safely treat HPV-positive head and neck cancer while reducing long-term side effects. About 304 participants will receive either standard or reduced radiation, with or without chemotherapy. The goal is to s…

This early-phase study tests a new drug called BL-B16D1 in about 21 adults with recurrent or metastatic head and neck squamous cell carcinoma or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, a…

This study tests a new care coordination system called PRONTO-HN for head and neck cancer patients. The system uses a risk model to identify patients likely to need radiation after surgery and then coordinates appointments and alerts to reduce delays. Researchers will compare 85 …

This early-phase trial is testing a new drug called RiMO-301, given as an injection directly into the tumor, along with radiation therapy and an immunotherapy drug (a PD-1 inhibitor). The goal is to see if this combination is safe and can shrink tumors in people with advanced hea…

This study tests a new surgical technique using a thin skin flap from the groin area to rebuild the mouth or throat after cancer removal. The goal is to see if it causes fewer problems at the donor site compared to standard flaps. Forty adults with head and neck cancer will be fo…

This early-stage trial is testing an experimental drug called LB1410, a bispecific antibody designed to block two immune checkpoints (PD-1 and TIM-3) and help the immune system fight cancer. It involves 100 adults with advanced solid tumors or lymphoma who have exhausted standard…

This study tests A2B395, a donor-derived CAR T-cell therapy designed to target cancer cells while sparing healthy ones. It is for adults with advanced solid tumors like colorectal, lung, or breast cancer that have lost a specific immune marker. The trial has two phases: first to …

This early-stage trial tests a new drug called NX-1607 in adults with advanced cancers that have not responded to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors. It includes people with several cancer types, such as ovarian, lung, an…

This study tests whether combining the immunotherapy drug tislelizumab with chemotherapy (paclitaxel, cisplatin, 5-FU) can shrink advanced head and neck tumors before surgery or chemoradiation. About 29 adults with stage III-IVb cancer will receive the combo for three cycles. Res…

The ORACLE study watches people who have finished treatment for early-stage solid tumors, such as lung, breast, colon, and pancreatic cancers. Researchers want to see if a blood test called Guardant Reveal can find tiny traces of tumor DNA that might signal the cancer is coming b…

This study tests whether a computer model that analyzes MRI images can predict which patients with head and neck cancer will have a complete response to neoadjuvant therapy, which combines chemotherapy and immunotherapy before surgery. Researchers will build the model using MRI s…

This study looks at whether PET/CT scans can accurately detect remaining cancer in lymph nodes after a person has completed curative radiation for head and neck cancer. About 600 adults who finished treatment will receive a PET/CT scan, and those with suspicious findings may unde…

This study is testing whether a special MRI technique can identify low-oxygen (hypoxic) regions within head and neck tumors. These areas are often resistant to treatment, so spotting them could help doctors personalize therapy. The trial will compare the MRI results with a standa…

This study is testing a new type of PET scan to see if it can tell the difference between cancer that is still there and swelling caused by radiation treatment in people with head and neck cancer. About 180 adults who finished radiation therapy will get this special scan 3 months…

This study tests whether a dye called ICG can help surgeons see tumor tissue more clearly during head and neck cancer surgery. About 30 adults with squamous cell carcinoma who are at risk of recurrence will receive the dye before surgery, and doctors will use a special camera to …

This early-stage trial tests a fluorescent dye attached to the cancer drug nivolumab. The dye is meant to make cancer cells glow during surgery, helping surgeons remove them more precisely. The study will enroll 40 people with head and neck cancer who are already scheduled for su…

This early-phase study tests a new radioactive tracer called [18F]NOTA-ABY030, which is designed to make head and neck squamous cell carcinoma show up more clearly on PET/CT scans. About 25 adults with suspicious or unclear findings on standard scans will receive the tracer and b…

This study tests a new imaging agent called 89Zr panitumumab to see if it can more accurately find cancer that has spread in people with head and neck cancer. Standard PET/CT scans often miss or wrongly identify these spots. About 60 participants will receive the new agent and th…

This early-phase study tests a radioactive tracer called [68Ga]Ga-ABY-025 for PET scans in 30 adults with advanced HER2-positive cancers (breast, gastric, head/neck, esophageal). Participants receive the tracer and a PET/CT scan before or during standard HER2-targeted therapy. Th…

This Phase 2 trial tests whether a special PET/CT scan using [68Ga]Ga-FAPI-46 can detect early lymph node metastases in people with head and neck squamous cell carcinoma. The scan targets cancer-associated fibroblasts, which help create a welcoming environment for cancer to sprea…

This study tests a dye called pegsitacianine that makes cancer cells glow during surgery. It is for 120 adults with head and neck cancer, including those with an unknown primary tumor. The goal is to see if the dye helps surgeons find and remove all cancer tissue safely.

This early-stage trial tests whether a radioactive imaging agent called 111In-panitumumab can help find cancer that has spread to lymph nodes in people with head and neck cancer. The agent binds to a protein common on cancer cells and lights up on a special scan. About 30 partici…

This study tests whether a dye called panitumumab-IRDye800 can make head and neck cancer cells glow during surgery, helping surgeons see and remove all cancer while sparing healthy tissue. About 25 adults with head and neck cancer scheduled for surgery will receive the dye before…

This early-phase study tests whether a special tracer called 89Zr panitumumab, used with PET/MRI scans, can show head and neck tumors more clearly than the standard FDG tracer. Fourteen newly diagnosed patients scheduled for surgery will receive both scans. The results are for re…

This early-phase trial is testing a new imaging agent (GEH200520/GEH200521) that lights up on PET scans to help see solid tumors. In Part A, 50 adults with advanced solid tumors will receive the agent and have scans to check safety and how the agent spreads in the body. Part B wi…

This early-stage study tests whether a protein called CFH, delivered through tiny ice microneedles, can prevent skin scarring caused by radiation therapy. Nine adults with head and neck cancer who will receive radiation after surgery are being enrolled. The main goals are to chec…

This study tests a new cream made from amino acids to prevent skin damage caused by radiation therapy in people with head and neck cancer. About 40 participants will use the cream during their radiation treatment. The goal is to see if it reduces skin redness, pain, and treatment…

This study tests a new way to give radiation to people with head and neck cancer. The goal is to see if protecting the parts of the throat used for swallowing can help patients eat and drink better after treatment. About 136 adults with certain types of head and neck cancer will …

This phase 3 trial tests whether a lozenge called BupiZenge, which contains the long-acting painkiller bupivacaine, can relieve mouth pain from radiation therapy better than the standard lidocaine rinse. About 150 adults with head and neck cancer will be randomly assigned to one …

This trial tests whether a mobile app that encourages social sharing and peer interaction can reduce anxiety and depression in people with head and neck cancer undergoing radiotherapy. Half of the 120 participants will use the app for eight weeks, while the other half receives a …

This study tests whether atorvastatin, a widely used cholesterol medication, can reduce hearing loss caused by cisplatin chemotherapy in people with head and neck cancer. About 224 adults will be randomly assigned to take atorvastatin or a placebo daily during and for three month…

This study looks at whether offering nutritional counseling and exercise programs before and during radiation or chemoradiation is helpful for head and neck cancer patients. Researchers want to see if patients are willing to join and attend these sessions. The goal is to improve …

This phase 2 trial tests whether adding olanzapine to standard care helps manage appetite loss in head and neck cancer patients undergoing chemoradiation. About 66 adults will receive either olanzapine plus standard symptom management or standard care alone. The main goal is to s…

This phase II trial tests whether adding BMX-001 to standard symptom management can reduce severe mouth sores in head and neck cancer patients receiving chemoradiation. About 98 participants will receive either BMX-001 or a placebo alongside usual care. The goal is to see if BMX-…

This phase 2 trial tests whether a modern radiation technique called stereotactic body radiotherapy (SBRT) can safely deliver a strong dose of radiation in just 3 to 5 sessions to relieve symptoms from head and neck cancer. The study involves 108 adults whose cancer cannot be cur…

This phase 1 trial tests whether d-limonene, a compound found in citrus peel, can safely prevent severe dry mouth (xerostomia) in people with head and neck cancer undergoing radiation and chemotherapy. Participants take d-limonene capsules daily during their standard cancer treat…

This study tests whether a drug called methylnaltrexone is safe for people with head and neck cancer when taken for two weeks before their surgery. The drug is already used for constipation, but researchers want to see if it can be given safely in this setting. About 25 adults wi…

This study compares giving the cancer drug nivolumab (Opdivo) as a shot at home versus in a clinic for people with various advanced cancers. The goal is to see if home treatment improves patients' overall care experience and quality of life. About 50 adults will receive the drug …

This pilot study tests whether a buried free fat flap surgery can safely reduce neck problems like pain, stiffness, and swallowing trouble in people treated for head and neck cancer. Twelve adults who need a salvage neck dissection will receive the fat flap procedure. Researchers…

This study tests if proton radiation causes fewer side effects than standard photon radiation in people with head and neck cancer. About 400 adults aged 40 and older will receive either proton or photon therapy, plus possible chemotherapy. The main goal is to see if protons reduc…

This study tests whether a high dose of gabapentin, a non-opioid pain medicine, can prevent the need for opioid painkillers in people with head and neck cancer who develop painful mouth sores from chemotherapy and radiation. About 228 participants will be randomly assigned to rec…

This study is testing a jelly-based nutritional supplement in 52 people with head and neck, lung, or rectal cancer who are receiving standard cancer treatments like chemo or radiation. The supplement contains ingredients like arginine, omega-3, and olive oil, and is taken twice d…

This study tests a new way to give radiation for head and neck cancer. Instead of a fixed plan, the radiation is adjusted daily to match changes in the patient's body. The goal is to lower side effects like trouble swallowing and dry mouth. About 40 adults with throat or voice-bo…

This phase II trial tests whether daily adaptive radiotherapy (DART) can better protect the submandibular glands during head and neck cancer treatment compared to standard image-guided radiation. About 50 participants will be randomly assigned to receive either standard or adapti…

This early-stage study tests a non-invasive procedure that uses focused ultrasound to create a tiny lesion in the brain's pain center. It is for 20 adults with head, neck, or brachial cancer whose pain is not controlled by opioids. The goal is to see if it is safe and can reduce …

This study tests a program called CARES that provides nurse navigators and counselors to rural cancer patients. The goal is to see if this support helps patients start and finish treatment more quickly and improves their quality of care. About 320 adults with solid tumors like lu…

This study compares standard radiation therapy to a newer method called dose painting for people with head and neck cancer. The goal is to see if dose painting causes fewer severe mouth ulcers one year after treatment. About 100 participants will be randomly assigned to receive e…

This study tests whether special training for caregivers of head and neck cancer patients can reduce the stress of caregiving and help patients recover better at home. About 76 caregivers will be split into two groups: one gets standard care, the other gets hands-on training from…

This study tests whether using a smartphone app to regularly report symptoms can help doctors catch problems early and reduce severe weight loss in head and neck cancer patients undergoing curative radiation or chemoradiation. About 192 adults will be enrolled. The goal is to see…

This study tests whether adding a special heat treatment (water-filtered infrared, or wIRA) to standard palliative radiation can help shrink tumors and ease symptoms in people with advanced head, neck, or skin cancer that cannot be cured. About 60 adults will receive the combined…

This study tests whether taking rice bran supplements can reduce severe mouth sores caused by radiation therapy in head and neck cancer patients. About 80 adults receiving radiation will take rice bran during treatment to see if it lessens pain and improves quality of life. The g…

This study tests whether a 20-week program of nutrition counseling, home-based exercise, and wellness education can reduce side effects and improve quality of life in 30 adults with head and neck cancer undergoing chemoradiation. The program includes weekly group sessions with a …

This study looks at whether getting immunotherapy infusions in the morning versus the afternoon changes outcomes for people with advanced lung cancer or head and neck cancer. About 238 participants will be randomly assigned to morning or afternoon infusions. Researchers will trac…

This study is testing whether a simple blood test that looks for tumor DNA can better detect any cancer left behind after radiation therapy for advanced head and neck cancer. Current scans often give false alarms, leading to unnecessary procedures. The study will enroll 63 adults…

This study looks at whether a simple blood test can find leftover cancer cells in people treated for advanced head and neck cancer. About 59 participants will give blood samples one and three months after finishing chemoradiotherapy. Researchers will compare the blood test result…

This study is for people newly diagnosed with head and neck squamous cell carcinoma who are scheduled for curative surgery or radiation therapy. Researchers want to see how radiation changes MRI scans and immune-related markers in tumors. About 40 participants will be randomly as…

This observational study collects tumor tissue and blood cells from 200 people with advanced solid tumors like colorectal, lung, and pancreatic cancers. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for potential fu…

This study enrolls 500 adults with advanced head and neck cancer who are starting standard immunotherapy. Researchers will collect blood and tumor samples over time to look for genetic and immune markers that may predict how well treatment works or why it stops working. The goal …

This study looks at how head and neck tumors change during treatment using special MRI scans and tissue samples. Sixty adults with newly diagnosed head and neck cancer will take a pill called pimonidazole, which highlights low-oxygen areas in tumors, and undergo repeat imaging. T…

This early-phase trial tests a fluorescent dye attached to the cancer drug panitumumab to help surgeons see head and neck cancer during surgery. 18 adults with head and neck squamous cell carcinoma will receive the dye before surgery, and a special camera will highlight cancer ti…

This study tests whether offering hearing tests close to home or remotely increases how many head and neck cancer patients get their hearing checked during treatment. Many patients on cisplatin chemotherapy or radiation near the ear can lose hearing, but not all complete recommen…

This study collects blood and tumor tissue samples from people with head and neck or lung cancers to find biological markers that indicate low oxygen levels within tumors. Low-oxygen tumors tend to be more aggressive and resistant to standard treatments like radiation and chemoth…

This study is collecting blood and tumor samples from 60 people with recurrent or metastatic head and neck cancer who are receiving standard anti-PD1 immunotherapy. The goal is to find biological markers that can predict whether the immunotherapy will work. Researchers will analy…

This study looks at whether eating more fiber can help head and neck cancer patients avoid muscle loss (sarcopenia). Researchers will track 59 adults from diagnosis for six months, measuring their fiber intake, muscle mass, and inflammation. The goal is to understand the link bet…

This study tests a high-resolution PET-CT scanner that images removed tumors right in the operating room. About 50 adults with solid cancers will get a standard PET tracer before surgery, then the removed tissue is scanned to see if all cancer was taken out. The goal is to see if…

This study looks at 220 people with HPV-related oropharynx cancer to see if certain gene mutations (TRAF3 and CYLD) and levels of HPV DNA in the blood can predict if the cancer will come back after treatment. Participants give blood samples and fill out quality-of-life questionna…

This study is testing whether advanced PET/MR imaging can help doctors personalize radiotherapy for head and neck cancer. Researchers will scan 390 patients before, during, and after treatment to see if imaging details can predict survival and response. The goal is to improve out…

This study looks at the genetic makeup of head and neck tumors from 1,000 people to find markers that predict how well a patient will respond to treatment and their chances of survival. Researchers will also search for new diagnostic markers. The goal is to better understand why …

This study follows 110 adults with head and neck, lung, or rectal cancer to see how their nutrition and body composition change during standard cancer treatments. Researchers will measure food intake, muscle mass, and strength over time. The goal is to gather data that could late…

This study looks at whether a simple blood test can give the same information about a tumor's biology as testing the tumor tissue itself. Researchers will collect blood samples from 300 adults with HPV-negative head and neck cancer before and after standard treatment. They will c…

This study is testing a new tool designed to predict side effects from cancer treatment in elderly patients (70+) with advanced head and neck cancer. The goal is to see if the tool can help doctors choose safer treatments. Only 3 participants are being enrolled, making this a ver…

This study is testing whether repeated MRI scans during radiation therapy for head and neck cancer can help doctors see how the tumor is responding. About 173 people with newly diagnosed head and neck cancer will get extra MRI scans during their standard treatment. The goal is to…

This study is testing whether a special PET scan taken 6 weeks after starting pembrolizumab (an immunotherapy drug) can predict how well the drug works at 3, 6, and 9 months in people with advanced head and neck cancer. Researchers will enroll 25 patients whose cancer has returne…

This observational study is testing a new blood test that uses a microfluidic chip to detect cancer cells and immune cells in 30 patients with recurrent or metastatic head and neck cancer. The goal is to see if these blood markers can predict how long patients live without their …

This study explores whether virtual reality and 3D models can help surgeons plan head and neck cancer operations more accurately. About 160 adults with head and neck cancer will take part. The goal is to see if this technology reduces the chance of leftover cancer cells and impro…

The RESCUE study is looking at 400 adults who have salvage surgery for head and neck cancer that came back after radiation. Researchers will track how long patients live without the cancer returning and how well they function after surgery. They will also analyze tumor tissue, bl…

This study looks at how head and neck cancer cells change after radiation treatment. Researchers will collect tissue and blood samples from 20 adults who had radiation before and are now having robotic surgery for new or returning tumors. The goal is to understand why some cancer…

This study looks at a blood test that measures tiny bits of tumor DNA floating in the blood. Researchers will enroll 50 adults with head and neck cancer who are planning surgery. They want to see how these DNA levels change after surgery and whether they can help predict if the c…

This study aims to find a unique chemical pattern (metabolomic signature) in blood, urine, and tumor samples from 250 people with upper aerodigestive tract cancers. By analyzing these samples before and after treatment, researchers hope to improve early detection, predict treatme…

This early-phase study is testing a small implantable device that delivers tiny amounts of different drugs directly into head and neck tumors. The goal is to see which drugs are most effective for each person before they undergo full treatment. The study involves 30 adults with c…

This early-phase trial is testing two new antibody fragments that are designed to attach to a sugar molecule found on many solid tumors. The fragments are labeled with a radioactive tracer so they can be seen on PET/CT scans. The study aims to see where these fragments go in the …

This study is testing whether measuring circulating tumor DNA (ctDNA) in the blood can predict if cancer will come back after radiation therapy. Researchers will collect blood samples from 188 patients with advanced head and neck cancer before, during, and after treatment. The go…

This study looks at whether a blood test that finds tumor DNA can predict if head and neck cancer comes back after treatment. About 250 adults who have finished curative treatment will give blood samples over time. The goal is to see if a positive test result matches cancer relap…

This study is for people with HPV-related throat cancer who have surgery to remove their tumor. Researchers are testing whether a blood test that looks for leftover tumor DNA can safely identify patients who do not need additional radiation. The goal is to reduce side effects by …

This study looks at how radiation therapy for head and neck cancers affects the blood vessels in the neck. Researchers will use two types of PET/CT scans to compare images taken before and after treatment. The goal is to better understand and detect radiation-related vascular dam…

This study is analyzing blood and tumor samples from 30 people with advanced head and neck cancer who are receiving standard immunotherapy plus chemotherapy. The goal is to find biological markers that can predict who will respond well to treatment. By understanding changes in th…

This observational study is collecting blood samples and medical images from 200 people with several types of solid tumors (like lung, head and neck, and esophageal cancers) who are receiving immunotherapy and radiation as part of their standard care. Researchers want to see if c…

This study enrolls 100 people with recurrent or metastatic head and neck squamous cell carcinoma. Researchers will take a small tumor sample, grow it in the lab as a 3D organoid, and test various drugs on it. They then compare the lab results to how the patient's actual tumor res…